Browse by People


Up a level
Export as [feed] RSS [feed] RSS 2.0 Short Author List
Number of items: 5.


Childs, Alexa, Zakeri, Nekisa, Ma, Yuk Ting, O'Rourke, Joanne, Ross, Paul, Hashem, Essam, Hubner, Richard A, Hockenhull, Kimberley, Iwuji, Chinenye, Khan, Sam
et al (show 9 more authors) (2021) Biopsy for advanced hepatocellular carcinoma: results of a multicentre UK audit. BRITISH JOURNAL OF CANCER, 125 (10). pp. 1350-1355.


Primrose, John N, Fox, Richard P, Palmer, Daniel H ORCID: 0000-0002-7147-5703, Malik, Hassan Z, Prasad, Raj, Mirza, Darius, Anthony, Alan, Corrie, Pippa, Falk, Stephen, Finch-Jones, Meg
et al (show 19 more authors) (2019) Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. LANCET ONCOLOGY, 20 (5). pp. 663-673.


Ghaneh, Paula, Palmer, Daniel, Cicconi, Silvia, Jackson, Richard, Halloran, Christopher Michael ORCID: 0000-0002-5471-4178, Rawcliffe, Charlotte, Sripadam, Rajaram, Mukherjee, Somnath, Soonawalla, Zahir, Wadsley, Jonathan
et al (show 26 more authors) (2022) Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. The lancet. Gastroenterology & hepatology, 8 (2). S2468-1253(22)00348-X-S2468-1253(22)00348-X.


De Souza, Shuell, de Jong, Jeffrey Kahol, Perone, Ylenia, Shetty, Shishir, Qurashi, Maria, Vithayathil, Mathew, Shah, Tahir, Ross, Paul, Temperley, Laura, Yip, Vincent SS
et al (show 9 more authors) (2023) Impact of COVID-19 on 1-Year Survival Outcomes in Hepatocellular Carcinoma: A Multicenter Cohort Study. CANCERS, 15 (13). 3378-.


Middleton, Gary, Palmer, Daniel H ORCID: 0000-0002-7147-5703, Greenhalf, William, Ghaneh, Paula, Jackson, Richard, Cox, Trevor, Evans, Anthony ORCID: 0000-0001-8547-1730, Shaw, Victoria E ORCID: 0000-0002-0429-0186, Wadsley, Jonathan, Valle, Juan W
et al (show 14 more authors) (2017) Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. The Lancet Oncology, 18 (4). pp. 486-499.

This list was generated on Sat Apr 6 11:34:40 2024 BST.